Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
DUROLANE Instructions for Use
04/13/2023 | Revision G:
DUROLANE Instructions for Use_Rev G
02/05/2020 | Revision F:
DUROLANE Instructions for Use_Rev F
12/20/2021 | Revision E:
DUROLANE Instructions for Use_Rev E
04/28/2016 | Revision D:
DUROLANE Instructions for Use_Rev D
01/28/2014 | Revision C:
DUROLANE Instructions for Use_Rev C
01/24/2014 | Revision B:
DUROLANE Instructions for Use_Rev B
03/19/2013 | Revision A:
DUROLANE Instructions for Use_Rev A
Summary of Instructions for Use
DUROLANE is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.
Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.
DUROLANE has not been tested in pregnant or lactating women, or children.
Full prescribing information can be found in package insert, at DUROLANE.com, or by contacting Bioventus Customer Service at 1-800-836-4080.
*First introduced in the European Union in 2001